Evidence map›Paper›PMID 28429112›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2017

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes.

Ute Walliczek-Dworschak, Volker Gudziol, Claudia Mitzschke, Michael Froehner, Thomas Hummel

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Taste and Smell Alterations (TSAs) in Cancer Patients.Diseases (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Nutrition and taste and smell dysfunction.World journal of otorhinolaryngology - head and neck surgery · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ute Walliczek-DworschakDepartment of Otorhinolaryngology, Smell and Taste Clinic, Interdisciplinary Center Smell and Taste, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. UteWalliczek@gmx.net.
Volker GudziolDepartment of Otorhinolaryngology, Smell and Taste Clinic, Interdisciplinary Center Smell and Taste, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Claudia MitzschkeDepartment of Otorhinolaryngology, Smell and Taste Clinic, Interdisciplinary Center Smell and Taste, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Michael FroehnerDepartment of Urology, Technische Universität Dresden, Dresden, Germany.
Thomas HummelDepartment of Otorhinolaryngology, Smell and Taste Clinic, Interdisciplinary Center Smell and Taste, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
TU Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testicular cancer is the most frequent malignant disease in young males between 15 and 35 years. Platinum based chemotherapy regimen is the therapy of choice in advanced disease. This treatment has also adverse effects caused by the cytostatic active substances, such as olfactory dysfunctions. The aim of this study was, therefore, to monitor olfactory function of testicular cancer patients during and 6 months after chemotherapy. A total of 17 patients (mean age 31.06 ± 10.26 years), which underwent chemotherapy (mean 2.47 cycles ± 0.5) were enrolled in this study. Odor threshold, discrimination and identification were assessed by means of the "Sniffin' Sticks" prior to and on day 42, 90 and 180 after chemotherapy has been completed. Furthermore, patients' ratings of olfactory function and depressive symptoms were evaluated. Threshold scores were significantly lower on day 90 (8.0 ± 2.51) compared to baseline (10.4 ± 2.20) (p = 0.014) and recovered almost completely on day 180 (9.65 ± 3.26). Odor discrimination and identification did not show significant changes during therapy. The decrease of the olfactory function during/immediately after chemotherapy was underlined by the subjectively perceived impaired olfactory function during this time. In addition almost every fourth patient presented with a depressed mood at the beginning of chemotherapy. Patients should be informed about possible transient olfactory impairment during/immediately after chemotherapy.

Indexed as

AdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCisplatinFemaleFollow-Up StudiesHumansMaleMiddle AgedOlfaction DisordersProspective StudiesSeminomaSensory ThresholdsSmellTesticular NeoplasmsAntineoplastic AgentsCisplatinOlfactionPlatinum based chemotherapySmellSniffin’ Sticks

Identifiers

PMID28429112
OpenAlexW2606368508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.